Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Apr;39(4):192-200.
doi: 10.1002/clc.22512. Epub 2016 Feb 16.

Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation

Affiliations
Randomized Controlled Trial

Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation

Jean-Philippe Collet et al. Clin Cardiol. 2016 Apr.

Abstract

There is an apparent benefit with extension of dual antiplatelet therapy (DAPT) beyond 1 year after implantation of drug-eluting stents (DES). Assessment by a Double Randomization of a Conventional Antiplatelet Strategy vs a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation, and of Treatment Interruption vs Continuation One Year After Stenting (ARCTIC)-Generation assessed whether there is a difference of outcome between first- vs second-generation DES and if there is an interaction with DAPT duration in the ARCTIC-Interruption study. ARCTIC-Interruption randomly allocated 1259 patients 1 year after stent implantation to a strategy of interruption of DAPT (n = 624), in which aspirin antiplatelet treatment only was maintained, or DAPT continuation (n = 635) for 6 to 18 additional months. The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization. A total of 520 and 722 patients received a first- and a second-generation DES, respectively. After a median follow-up of 17 months (interquartile range, 15-18 months) after randomization, the primary endpoint occurred in 32 (6.2%) and 19 (2.6%) patients with first- and second-generation DES, respectively (hazard ratio: 2.31, 95% confidence interval: 1.31-4.07, P = 0.004). This was observed irrespective of the strategy of interruption or continuation of DAPT and timing of study recruitment. Major bleeding events occurred in 4 (0.8%) and 3 patients (0.4%) with first- and second-generation DES, respectively (hazard ratio: 1.79, 95% confidence interval: 0.40-8.02, P = 0.44). Results did not change after multiple adjustments for potential confounding variables. ARCTIC-Generation showed worse clinical outcome with first- vs second-generation DES, a difference that appeared to persist even with prolonged DAPT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier curve for the primary endpoint (death, MI, ST, stroke, or urgent revascularization). Abbreviations: HR, hazard ratio; MI, myocardial infarction; ST, stent thrombosis.

References

    1. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators . Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents. N Engl J Med. 2014;371:2155–2166. - PMC - PubMed
    1. Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel‐eluting coronary stent placement. Circulation. 2015;131:62–73. - PubMed
    1. Stone GW, Rizvi A, Newman W, et al; SPIRIT IV Investigators . Everolimus‐eluting versus paclitaxel‐eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–1674. - PubMed
    1. Stefanini GG, Baber U, Windecker S, et al. Safety and efficacy of drug‐eluting stents in women: a patient‐level pooled analysis of randomised trials [published correction appears in Lancet. 2013;382:1878]. Lancet. 2013;382:1879–1888. - PubMed
    1. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug‐eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR‐TEST 3, ISAR‐TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214–1222. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources